Amivantamab Provides Long-Term Benefit in Heavily Pretreated

Amivantamab can provide a long-term benefit in NSCLC patients with EGFR exon 20 insertions whose disease progressed on platinum-based chemotherapy.

Related Keywords

Madrid , Spain , Pilar Garrido , Universitario Ramony Cajal , Janssen Research Development , European Lung Cancer Congress , Hospital Universitario Ramon , Janssen Research ,